Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 8Completed 4Terminated 3Not yet recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 299Solid Tumors 184Advanced Solid Tumors 168Solid Tumor 152Mesothelioma, Malignant 152Mesothelioma 121Advanced Solid Tumor 97Carcinoma, Non-Small-Cell Lung 50Retinoblastoma 48Lung Neoplasms 37Solid Tumor, Adult 36Sarcoma 31Ovarian Neoplasms 29Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Small Cell Lung Carcinoma 25Melanoma 25Pancreatic Neoplasms 24Breast Neoplasms 24Unspecified Childhood Solid Tumor, Protocol Specific 23Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Solid Tumours 20Solitary Fibrous Tumor, Pleural 19Osteosarcoma 19Colorectal Neoplasms 17Neuroblastoma 16Head and Neck Neoplasms 16Carcinoma, Hepatocellular 16

Interventions

vanucizumab 1selicrelumab 1pembrolizumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Advanced/Metastatic Solid Tumors × Other solid neoplasm × Clear all
NCT04501276 2026-01-08

A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients

Adagene Inc

Phase 1 Completed
72 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT04645069 2024-08-14

ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1/2 Completed
58 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT05277402 2024-02-26

ADG116 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Adagene Inc

Phase 1 Completed
6 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

NCT02665416 2020-04-07

Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
94 enrolled
Other solid neoplasm

Advanced/Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡